CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to < 18 Years of Age) With Primary Immunoglobulin A Nephropathy (IgAN)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07024563
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:12.774640+00:00
Published At: 2026-03-17T00:00:00+00:00
Record Updated At: 2026-03-17
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["IgAN", "IgAVN", "Immunoglobulin A Nephropathy", "Immunoglobulin A Vasculitis Associated Nephritis", "Henoch-schonlein Purpura Nephritis", "IgA Vasculitis"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-03-17"
protocolSection.identificationModule.nctId: "NCT07024563"
protocolSection.identificationModule.officialTitle: "A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to \u003c 18 Years of Age) With Primary Immunoglobulin A Nephropathy (IgAN)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.